Search Results
Showing Results for efficacy
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
The 17th ATTD Conference (Amsterdam, 19–22 March 2025) showcased major innovations in diabetes care. The 15-day Dexcom G7 CGM proved accurate and user-friendly. The RADIANT trial showed Omnipod® 5 significantly improved glucose control over injections in type 1 diabetes. In type 2 diabetes, the 2IQP Study highlighted benefits of AID systems. Teplizumab also showed potential to enhance glycaemic stability in newly diagnosed type 1 diabetes, reinforcing the role of technology and immunotherapy in advancing diabetes management.
Eneboparatide is an investigational parathyroid hormone receptor 1 (PTH1R) agonist, designed to bind with high affinity to a specific conformation of PTH1R, which is expressed in the kidneys and bone. The goal of treatment is to restore function by producing sustained and stable levels of calcium in the blood and by restoring calcium reabsorption by the kidney.2,3 Eneboparatide has been developed to have a short half-life in order to preserve bone health.
Diabetes is a chronic disease associated with both acute and chronic complications. Many advances have been introduced throughout history to address these problems. While each clinical breakthrough was welcomed with relief and the expectation that a solution had been discovered, ...
Article Highlights This study aims to find an effective and affordable biomarker panel for early non-alcoholic fatty liver disease (NAFLD) detection in Indian women with morbid obesity, given the rising prevalence of NAFLD and limited accessibility of ultrasound sonography (USG) ...
Article Highlights Early use of sodium–glucose co-transporter-2 inhibitors following myocardial infarction was associated with the following factors: Lower hospitalization for heart failure (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62–0.90; p=0.002). Similar cardiovascular deaths (OR: 1.04; 95% CI: 0.83–1.30; p=0.76). Similar all-cause mortality (OR: 1.00; 95% ...
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age and is characterized by hyperandrogenism, anovulation and insulin resistance (IR).1 Women with PCOS have a high risk of developing type 2 diabetes (T2D), dyslipidaemia, hypertension and ...
As 2024 draws to a close, we’re celebrating a wonderful year of content.
Very few trials in the history of medical science have altered the treatment landscape as profoundly as the UK Prospective Diabetes Study (UKPDS). Even 44 years after its inception, the trial and post-study follow-up findings continue to fascinate and enlighten the ...
It is with great pleasure that we present this latest issue of touchREVIEWS in Endocrinology, which brings together a diverse array of high-quality articles focused on the evolving landscape of endocrine disorders. The importance of patient-centred care is exemplified in ...
MACE reduction was a key finding in the topline results from the Semaglutide Cardiovascular Outcomes Trial (SOUL), which reported that oral semaglutide, a long-acting Glucagon-Like Peptide-1 (GLP-1) receptor agonist, significantly decreases the risk of major adverse cardiovascular events in adults with type 2 diabetes (T2D) who have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).
This systematic review and meta-analysis investigate the efficacy of teprotumumab, a novel monoclonal antibody, in reducing proptosis for patients with long-duration thyroid eye disease (TED). While teprotumumab has shown promise in treating active TED, its effectiveness in chronic cases remained ...
Dry eye disease (DED) is known as dry eye syndrome (DES) or keratoconjunctivitis sicca. According to the Tear Film and Ocular Surface Society’s Dry Eye Workshop II (TFOS DEWS II), it constitutes a multifactorial disease of the ocular surface, ...
The prevalence of diabetes during pregnancy is rapidly increasing. In the USA alone, an estimated 1–2% of pregnant women have type 1 diabetes (T1D) or type 2 diabetes (T2D), and an additional 6–9% develop gestational diabetes.1 From 2000 to 2010, the prevalence of gestational ...
Hepatic steatosis is the liver manifestation of metabolic syndrome and a common cause of chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) diagnosis relies on the presence of hepatic steatosis, defined as >5% fat accumulation in the liver, as observed ...
touchENDOCRINOLOGY was delighted to speak with Editorial Board member Dr Deep Dutta, a senior endocrinologist at the CEDAR Superspecialty Clinics, New Delhi, India. Throughout this interview, he summarizes the key messages from his late-breaking abstract session ‘Ailing Heart, Broken Vessels’, presented at the 60th European Association for the Study of Diabetes (EASD) annual meeting in Madrid, Spain.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
